<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCT</journal-id><journal-title-group><journal-title>Journal of Cancer Therapy</journal-title></journal-title-group><issn pub-type="epub">2151-1934</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jct.2019.109062</article-id><article-id pub-id-type="publisher-id">JCT-94957</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Epidemiological and Clinical Profile of Breast Cancer at Bamako Radiotherapy Center
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>A.</surname><given-names>S. Kone</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>A.</surname><given-names>Diakite</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>I.</surname><given-names>M. Diarra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>K.</surname><given-names>Diabate</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>M.</surname><given-names>A. Camara</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Y.</surname><given-names>L. Diallo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>S.</surname><given-names>Sidibe</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Radiotherapy Center, Mali Hospital, Bamako, Mali</addr-line></aff><aff id="aff4"><addr-line>Department of Radiology, Point G Hospital, Bamako, Mali</addr-line></aff><aff id="aff3"><addr-line>Department of Medicine and Endocrinology, Bamako Hospital, Bamako, Mali</addr-line></aff><aff id="aff2"><addr-line>Radiology Department, Mali Hospital, Bamako, Mali</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>09</month><year>2019</year></pub-date><volume>10</volume><issue>09</issue><fpage>739</fpage><lpage>746</lpage><history><date date-type="received"><day>2,</day>	<month>July</month>	<year>2019</year></date><date date-type="rev-recd"><day>8,</day>	<month>September</month>	<year>2019</year>	</date><date date-type="accepted"><day>11,</day>	<month>September</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Breast cancer is a major public health problem because of its incidence and mortality. Purpose: To establish the epidemiological and clinical characteristics of breast cancer seen at the radiotherapy center at the Mali Hospital of Bamako. Patients and methods: It was a retrospective, descriptive study of data from patients seen for breast cancer at the Center of Radiotherapy of Mali Hospital between April 2014 and December 2016. The parameters studied were: age, sex, family history of breast cancer, menopausal status, parity, breast tumor location, histological type, histological grade, cancer classification stage. Results: 134 cases of breast cancer were collected, with a frequency of 15%. The sex ratio (H/F) of 0.007. The patient’s mean age was 47 &#177; 11 years old. The most represented age groups were 33 - 47 years old with 45.5% and 48 - 62 years old with 39%. Three percent (3%) of patients had a family history of breast cancer. Fifty (50%) of the patients were menopausal. The main clinical signs found 
  were :
   mammary nodules (98%), mastodynia (65%), nodes (67%). Invasive ductal carcinomas were found in 94% of patients, followed by infiltrating lobular carcinomas with 3.7% and metaplastic carcinomas with 1.7%. SBR Grade
  s
   II
   and
   III w
  ere
   mostly found with 37% and 23%. The average tumor size was 87
   
  mm &#177; 43. Stage III was predominantly represented with 72%, followed by Stage II with 24% and Stages I and IV with 2% each. Conclusion: Breast cancer is common and reaches both before and after 50 years; the diagnosis is usually late; hence 
  it is 
  the importance of raising awareness and screening b
  efore the age of 50 and popularizing some complementary tests to better understand the prognosis of this disease and promote more targeted and conservative treatments 
  that 
  will improve survival.
 
</p></abstract><kwd-group><kwd>Breast Cancer</kwd><kwd> Epidemiology</kwd><kwd> Clinic</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Breast cancer is characterized by the uncontrolled development of cancer cells in the mammary gland. It is a major public health problem because of its high incidence and mortality. With 2.088.849 new cases identified (11.6%) and 626.679 (6.6%) cases of death worldwide, it accounts for 25.1% of all cancers [<xref ref-type="bibr" rid="scirp.94957-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.94957-ref2">2</xref>] .</p><p>The incidence of breast cancer is 4 to 10 times higher in Western countries (mainly in the United States and Northern Europe) compared to Asia and Africa [<xref ref-type="bibr" rid="scirp.94957-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.94957-ref3">3</xref>] .</p><p>In sub-Saharan Africa, the incidence of breast cancer varies by country [<xref ref-type="bibr" rid="scirp.94957-ref4">4</xref>] ; in Mali, from 2006 to 2010 it is in second place after the cervix, with a relative frequency of 18.7%, it is the second cause of cancer death after cervical cancer [<xref ref-type="bibr" rid="scirp.94957-ref5">5</xref>] . It is currently first cancer in terms of incidence according to the 2010-2017 Bamako cancer registry.</p><p>To our knowledge, in Mali, there are no published data on the epidemiological and clinical characteristics of this cancer. This is why, in this work, we propose to study the epidemiological and clinical characteristics of breast cancer treated at the radiotherapy center of the Mali Hospital of Bamako.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>This was a retrospective and descriptive study of the data of patients monitored for breast cancer at the Bamako Radiotherapy Center of the Mali Hospital, between April 2014 to December 2016.</p><p>Included in the study was any case of histologically proven breast cancer and seen at the radiotherapy center for management, regardless of age and gender. Patients with no histological diagnosis were not included in this study.</p><p>The data was collected from the patient’s medical records and the radiotherapy department’s registry.</p><p>The parameters studied were: age, sex, family history of breast cancer, menopausal status, parity, breast tumor location, histological type, histological grade, stage of classification of the breast. Cancer.</p><p>The classification of cancers was based on the clinical examination according to the location of the primitive and on the extension assessment.</p><p>The clinical examination specified if possible the size of the tumor as well as its extensions. The radiological examinations were most often a mammography coupled with an ultrasound, a chest x-ray, an abdominopelvic ultrasound and/or a thoraco-abdominopelvic CT scan. Bone scans were not requested because they were not feasible in Mali. The search for hormonal receptors and the Her 2 neu membrane receptor by immunohistochemistry was also not feasible in Mali during the study period. The seventh edition of the TNM classification of the International Union against Cancer (UICC) was used for staging [<xref ref-type="bibr" rid="scirp.94957-ref6">6</xref>] . Data analysis was done using SPSS23.0 software.</p></sec><sec id="s3"><title>3. Results</title><p>Epidemiological characteristics:</p><p>From April 2014 to December 2016, we received 890 cases of cancer including 134 cases of breast cancer, a frequency of 15%. With only one man the sex ratio (H/F) was 0.007. The mean age of our patients was 47 &#177; 11 years with extremes ranging from 18 to 88 years. The most represented age groups were 33 - 47 years old with 45.5% and 48 - 62 years old with 38.8% (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Clinical features:</p><p>In the cohort, 3% of patients had a family history of breast cancer. They were pauciparous in 59%, multiparous in 32% of cases and nulliparous in 8% of cases. At the time of diagnosis, 50% of the patients were menopausal.</p><p>The clinical sign of discovery was a mammary nodule in 98% of patients. Mastodynia was found in 65% of patients. In 67%, lymph node involvement was the mode of revelation. Nipple discharge was present in 18%, the appearance of orange peel was found in 4% and ulceration in 16% (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Paraclinical aspects:</p><p>Ultrasound was performed in all patients. It was coupled with mammography in 94% of cases.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of the study population</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >EFFECTIVE (N = 134)</th><th align="center" valign="middle" >PERCENTAGE %</th></tr></thead><tr><td align="center" valign="middle" >AGE</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Mean M&#233;dian Extreme</td><td align="center" valign="middle" >47 &#177; 11 years 47 years [18 - 88] years</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >AGE GROUPS</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >18 - 32 years 33 - 47 years 48 - 62 years 63 - 77 years 78 - 92 years</td><td align="center" valign="middle" >10 61 52 10 1</td><td align="center" valign="middle" >7.5 45.5 38.8 7.5 0.7</td></tr><tr><td align="center" valign="middle" >FAMILY ANTECEDENT OF BREAST CANCER</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >NO YES</td><td align="center" valign="middle" >130 4</td><td align="center" valign="middle" >97.0 3.0</td></tr><tr><td align="center" valign="middle" >PARITY</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Multiparous Not applicable Nulliparous Paucipare</td><td align="center" valign="middle" >43 1 11 79</td><td align="center" valign="middle" >32.1 0.7 8.2 59.0</td></tr><tr><td align="center" valign="middle" >MENOPAUSE</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No Yes</td><td align="center" valign="middle" >65 68</td><td align="center" valign="middle" >48.5 50.7</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Characteristics of the study population</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >EFFECTIVE (N = 134)</th><th align="center" valign="middle" >PERCENTAGE %</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >LOCATION OF CANCER</td></tr><tr><td align="center" valign="middle" >Bilat&#233;ral Breast Right breast Left breast</td><td align="center" valign="middle" >2 52 80</td><td align="center" valign="middle" >1.5 38.8 59.7</td></tr><tr><td align="center" valign="middle"  colspan="3"  >CIRCUMSTANCES OF DISCOVERIES</td></tr><tr><td align="center" valign="middle" >NODULE No Yes Mastodynia No Yes AXILLARY ADENOPATHY No Yes MAMELONARY FLOW No Yes ORANGE PEEL No Yes ULCERATION No Yes</td><td align="center" valign="middle" >2 132 47 87 44 90 109 25 129 5 112 22</td><td align="center" valign="middle" >1.5 98.5 35.1 64.9 32.8 67.2 81.3 18.7 96.3 3.7 83.6 16.4</td></tr><tr><td align="center" valign="middle" >HISTOLOGICAL TYPE</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CCI CLI CMI Phyllode sarcoma</td><td align="center" valign="middle" >126 5 2 1</td><td align="center" valign="middle" >94 3.7 1.5 0.7</td></tr><tr><td align="center" valign="middle" >GRADING SCARFF BLOOM OF RICHARDSON (SBR)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SBR I SBR II SBR III Unspecified</td><td align="center" valign="middle" >6 50 31 47</td><td align="center" valign="middle" >4 .47 37.31 23.13 35</td></tr></tbody></table></table-wrap><p>Histologically, infiltrating ductal carcinoma was found in 94% of patients. It was followed by infiltrating lobular carcinomas (3.7%) and metaplastic carcinomas with 1.7%. Sarcomas were found in 0.7% of cases. The rank of Scarff Bloom and Richardson (SBR), could be evaluated in 65% of which 4% of Grade I, 37% of Grade II and 23% of Grade III.</p><p>As part of the extension assessment, 76% of patients had chest X-rays and 99% had abdominal ultrasonography. Thoracoabdominopelvic CT was performed in 60% of patients (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Characteristics of the study population</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >EFFECTIVE (N = 134)</th><th align="center" valign="middle" >PERCENTAGE %</th></tr></thead><tr><td align="center" valign="middle" >PARACLINIC EXAMINATIONS MAMMOGRAPHY No Yes BREAST ULTRASOUND No Yes X-Ray Chest No Yes ABDOMINAL ULTRASOUND No Yes SCANNER THORACO-ABDOMINO &#177; PELVIAN No Yes</td><td align="center" valign="middle" >8 126 0 134 32 102 1 133 54 80</td><td align="center" valign="middle" >6.0 94.0 0 100.0 23.9 76.1 0.7 99,3 40.3 59.7</td></tr><tr><td align="center" valign="middle" >SIZE OF TUMOR Average Median extremes</td><td align="center" valign="middle" >86.85 &#177; 42.839 mm 93 mm [6 - 182] mm</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CLASSIFICATION TNM UICC 7<sup>th</sup> EDITION TUMOR T1 T2 T3 T4 ADENOPATHY N0 N1 N2 N3 METASTASIS M0 M1</td><td align="center" valign="middle" >6 23 42 63 43 51 24 16 131 3</td><td align="center" valign="middle" >4.5 17.2 31.3 47.0 32.1 38.1 17.9 11.9 97.8 2.2</td></tr><tr><td align="center" valign="middle" >STADING IA IIA IIB IIIA IIIB IIIC IV</td><td align="center" valign="middle" >3 23 9 29 52 15 3</td><td align="center" valign="middle" >2.2 17.2 6.7 21.6 38.8 11.2 2.2</td></tr></tbody></table></table-wrap><p>Mean tumor size was 87 &#177; 43 mm with extremes ranging from 6 to 182 mm. Patients were graded and staged according to the criteria of the seventh edition of the TNM classification of the International Union against Cancer (UICC). Thirty-one (31%) of the patients had a tumor size greater than 5 cm. In 47% of cases, the tumor was extended to the chest wall and/or the skin. The ipsilateral axillary lymphadenopathies were found in 38% of patients, while 18% had fixed homolateral axillary adenopathies and 12% had supraclavicular lymphadenopathies. Three percent of the patients had secondary locations. Stage III was predominantly represented with 72%, followed by stage II with 24% and stages I and IV with 2% each (<xref ref-type="table" rid="table3">Table 3</xref>).</p></sec><sec id="s4"><title>4. Discussion</title><p>Breast cancer is the first cancer in the world [<xref ref-type="bibr" rid="scirp.94957-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.94957-ref2">2</xref>] . In 33 months, at the Radiotherapy Center of the Mali Hospital, we collected 134 cases out of 890 cases of cancer (15%), an average of 30.25 cases per year. In Africa the incidence of breast cancer varies between countries. So in Niger, Zaki et al. report 64.5 cases per year [<xref ref-type="bibr" rid="scirp.94957-ref7">7</xref>] , in Togo, Darr&#233; et al., Report 22.5 cases per year [<xref ref-type="bibr" rid="scirp.94957-ref8">8</xref>] . Overall this frequency found in Africa is lower than in Europe and represents 24.2% [<xref ref-type="bibr" rid="scirp.94957-ref1">1</xref>] .</p><p>In our study, women accounted for 99.2% of cases, a sex ratio (M/F) of 0.007. This result is lower than those reported in Niger and Togo which were respectively 0.03 and 0.023 [<xref ref-type="bibr" rid="scirp.94957-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.94957-ref8">8</xref>] . This could be explained by the fact that our study was monocentric. For some authors, the rarity of breast tumors in the male sex is explained by the atrophic nature of the gland, the delicacy of the milk ducts, the absence of acini and the abundance of fibrous tissue in man [<xref ref-type="bibr" rid="scirp.94957-ref9">9</xref>] .</p><p>As for age, the extremes ranges from 18 and 88 years old, with an average age of 47 &#177; 11 years. These results are comparable to those found in Cameroon [<xref ref-type="bibr" rid="scirp.94957-ref4">4</xref>] . In our series, breast cancer was common in both patients before and after 50 years. The most represented age groups were respectively 33 - 47 years old with 45.5% and 48 - 62 years old with 39% while in the Cameroonian series 17% of the patients were between 45 - 49 years old [<xref ref-type="bibr" rid="scirp.94957-ref4">4</xref>] . In Niger, Zaki et al. found 69.89% of breast cancers in women before age 50 [<xref ref-type="bibr" rid="scirp.94957-ref7">7</xref>] . The results found in Africa are different from those found in the USA or 50% of cases of breast cancer are diagnosed in women over 65 years. In Europe, the incidence of breast cancer is 210 per 100,000 for women aged 50 - 54 and more than 300 per 100,000 women at age 70 [<xref ref-type="bibr" rid="scirp.94957-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.94957-ref11">11</xref>] .</p><p>In our family history study, so-called hereditary breast cancer is rare with a frequency of 3%. This result is significantly lower than the Cameroonian and Tunisian studies, which had recovered respectively 23% and 13.23% [<xref ref-type="bibr" rid="scirp.94957-ref12">12</xref>] .</p><p>Conventionally, multiparity is a factor in reducing the risk of breast cancer, in our series, 32% of patients were multiparous. This result is lower than that of Sano et al. (7) with 54% multiparas among women with breast cancer in Burkina Faso [<xref ref-type="bibr" rid="scirp.94957-ref13">13</xref>] . Breast cancer was diagnosed in 48.5% of premenopausal patients, which is lower than the study by Dem et al. Who found that 57.3% of these malignancies are diagnosed before age 50 [<xref ref-type="bibr" rid="scirp.94957-ref14">14</xref>] .</p><p>The tumoral involvement concerned the left breast in 60% of cases, comparable to the Guinean series which found a frequency of 56% [<xref ref-type="bibr" rid="scirp.94957-ref15">15</xref>] . In 1.5% of cases the involvement was bilateral, in the literature the bilateral involvement varies between 3% - 13% [<xref ref-type="bibr" rid="scirp.94957-ref16">16</xref>] . Regarding the circumstances of discovery, the self-examination of nodules was found in 98% of patients, which may or may not be associated with mammalian mastodynia and axillary adenopathy in more than 60% of cases, whereas in the Tunisian series, the nodule was present. at 81.4% [<xref ref-type="bibr" rid="scirp.94957-ref17">17</xref>] .</p><p>Histologically, there was a preponderance of infiltrating ductal carcinomas with 94%, followed by infiltrating lobular carcinoma with 3.7% and metaplastic carcinoma with 1.7%. These results are comparable to the Moroccan and Cameroonian series but with different proportions [<xref ref-type="bibr" rid="scirp.94957-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.94957-ref18">18</xref>] .</p><p>There was a predominance of SBR grade II in our patients, which corroborates with the Cameroonian study which also found a higher frequency of grade II SBR (66%), followed by Grades III and I with 20% and 14% [<xref ref-type="bibr" rid="scirp.94957-ref4">4</xref>] . However it should be noted that 35% of our patients had not been able to benefit from this grading. Immunohistochemistry was not practiced during the study period; no patient was able to benefit from a search for hormonal receptors and Her2neu.</p><p>In our series, the average tumor size was 87 mm, much higher than the patients of the Moroccan series which was 36 mm, this could be explained by a lack of awareness and screening on breast cancer in Mali.</p><p>Stages II and III were predominantly represented with 24% and 72%, thus requiring much more radical treatments. Bouchbika Z et al.; had demonstrated the value of early diagnosis and mammography screening, which increased from 2004-2009 to Ibn Rochd Hospital in Casablanca, stages II and III from 50% and 30% to 54% and 16%; which makes it possible to increase the rate of conservative treatments [<xref ref-type="bibr" rid="scirp.94957-ref3">3</xref>] .</p><p>Our results concern the only cancer treatment center by radiotherapy in Mali, but are comparable to those of the Bamako cancer registry.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In our context breast cancer remains a major public health problem; in our series, we find a slight predominance of subjects under 50 years. The diagnosis is usually late in our context, hence it is the importance of raising awareness and screening before the age of 50. This will promote more conservative and targeted treatments that will improve patient survival.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Kone, A.S., Diakite, A., Diarra, I.M., Diabate, K., Camara, M.A., Diallo, Y.L. and Sidibe, S. (2019) Epidemiological and Clinical Profile of Breast Cancer at Bamako Radiotherapy Center. Journal of Cancer Therapy, 10, 739-746. https://doi.org/10.4236/jct.2019.109062</p></sec></body><back><ref-list><title>References</title><ref id="scirp.94957-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="scirp.94957-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Youlden, D.R., Cramb, S.M., Dunn, N.A., et al. (2012). The Descriptive Epidemiology of Female Breast Cancer: An International Comparison of Screening, Incidence, Survival and Mortality. Cancer Epidemiology, 36, 237-248. 
https://doi.org/10.1016/j.canep.2012.02.007</mixed-citation></ref><ref id="scirp.94957-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bouchbika, Z., Serhier, Z., Sahraoui, S., Bennani-Othmani, M. and Benider, A. (2012) Stade du cancer du sein lors du diagnostic: Impact des campagnes de sensibilisation. Pratiques et Organisation des Soins, 43, 269-275.  
https://doi.org/10.3917/pos.434.0269</mixed-citation></ref><ref id="scirp.94957-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ndamba Engbang, J.P., Essome, H., Mve Koh, V., Simo, G., Sime Essam, J.D., Sone Mouelle, A. and Oyono Essame, J.L. (2015) Cancer du sein au Cameroun, profil histo-épidémiologique: à propos de 3044 cas. The Pan African Medical Journal, 21, 242. https://doi.org/10.11604/pamj.2015.21.242.7269</mixed-citation></ref><ref id="scirp.94957-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Traore, C.B., Coulibaly, B., Malle, B., Kamate, B., et al. (2012) Le cancer a bamako de 2006 a 2010. Données du registre des cancers au Mali. Revue Africaine de Pathologie Juin, 11.</mixed-citation></ref><ref id="scirp.94957-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sobin, L., et al. (2009) Classification TNM 7ième  édition de l’Union Internationale Contre le Cancer (UICC).</mixed-citation></ref><ref id="scirp.94957-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zaki, H.M., Garba-Bouda, O., Garba, S.M. and Nouhou, H. (2013) Profil épidémiologique et anatomopathologique du cancer du sein au Niger. African Journal of Cancer, 5, 185-191. https://doi.org/10.1007/s12558-013-0274-9</mixed-citation></ref><ref id="scirp.94957-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Darré, T., Amegbor, K., Sonhayé, L., Kouyate, M., Aboubarak, A., N’Timo, B., et al. (2013) Profil histo-épidémiologique des cancers du sein: à propos de 450 cas observés au CHU de Lomé. Médecine d’Afrique Noire électronique, 60, 53-58.</mixed-citation></ref><ref id="scirp.94957-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ioanmidou, L., Mouzakal, N.J., Agnantis, H. and Mahera, N.X. (1987) Papacharacampous. Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 16, 851-860.</mixed-citation></ref><ref id="scirp.94957-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Robert, J. and Kenn, M.C. (1994) Clinical Aspect of Cancer in the Elderly. Cancer, 74, 2107-2117.</mixed-citation></ref><ref id="scirp.94957-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Naik, A.M., Joseph, K., Harris, M., Davis, C., Shapiro, R. and Hiotis, K.L. (2003) Indigent Breast Cancer Patients among All Racial and Ethnic Groups Present with More Advanced Disease Compared with Nationally Reported Data. The American Journal of Surgery, 186, 400-403. https://doi.org/10.1016/S0002-9610(03)00282-4</mixed-citation></ref><ref id="scirp.94957-ref12"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eisinger</surname><given-names> F. </given-names></name>,<etal>et al</etal>. (<year>2005</year>)<article-title>Le dépistage des cancers du sein chez la femme à haut risque familial</article-title><source> Bulletin du Cancer</source><volume> 92</volume>,<fpage> 874</fpage>-<lpage>884</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.94957-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sano, D.I., Cisse, R., Dao, B., Lankoande, J., Traore, S.S.L., Soudre, R.B., et al. (1998) Le cancer du sein: Problèmes diagnostiques et thérapêutiques au CHU de Ouagadougou. Médecine d’Afrique Noire, 45, 297-301.</mixed-citation></ref><ref id="scirp.94957-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Dem, A., Traoré, B., Dieng, M.M., et al. (2006) Cancers gynécologiques et mammaires à l’Institut Curie de Dakar (Sénégal). Oncol Clin Afr, 2, 17-21.</mixed-citation></ref><ref id="scirp.94957-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Diallo, M.S., Diallo, T.S., Diallo, S.B., Camara, N.D., Diallo, F.B., Dieng, A., Diallo, Y. and Diaw, S.T. (1996) Les tumeurs du sein: épidémiologie, clinique, anatomie pathologique et pronostic. Médecine d’Afrique Noire, 43.</mixed-citation></ref><ref id="scirp.94957-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Cucinotta, E., Calbo, L., Palmeri, R., Pergolizzi, F.P. and Melita, G. (1996) Bilateral Carcinoma of the Breast. Chirurgia italiana, 49, 914.</mixed-citation></ref><ref id="scirp.94957-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Jihen, J., Habib, A., Nabil, T., et al. (2010) Le cancer du sein chez la femme agée epidémiologie et caractéristiques cliniques. JIM Sfax, No. 19/20, 36-46.</mixed-citation></ref><ref id="scirp.94957-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Abbass, F., Bennis, S., Znati, K., Akasbi, Y., Amrani, J.K., El Mesbahi, O. and Amarti, A. (2011) Le profil épidémiologique et biologique du cancer du sein à Fès-Boulemane (Maroc). Eastern Mediterranean Health Journal, 17.</mixed-citation></ref></ref-list></back></article>